Dr. Samuel Browd is a Professor of Neurological Surgery at the University of Washington and Attending Neurosurgeon at Seattle Children's Hospital, holding an M.D./Ph.D. from the University of Florida where he studied neuroplasticity and learning, and recognized as the 2021 Congress of Neurological Surgeons Innovator of the Year. He has co-founded multiple venture-backed startups including VICIS, Proprio, Aqueduct Neuroscience, NeuFluent, and DeepWell, co-developed three products listed as Time Magazine's Invention of the Year in 2017, 2019, 2021 and 2025 and through Digital Fluency has partnered with AANS and CNS to advance neurosurgical education in AI, immersive medicine, surgical robotics, and digital innovation.

Craig Mundie is the former Chief Research and Strategy Officer at Microsoft (2006-2014) and current President of Mundie & Associates, where he counsels CEOs on strategic issues involving rapidly-evolving information technologies. He served on President Obama's Council of Advisors on Science and Technology (PCAST) and was Microsoft's principal technology-policy liaison to governments worldwide, with particular expertise in cybersecurity and techno-geopolitics

Scott Phillips is the Founder and CEO of StarFish Medical, Canada's largest medical device design company, which he established in 1999 and has grown into a prominent player serving clients worldwide with over 230 full-time staff across North America. Holding a degree in Engineering Physics from the University of British Columbia, he is a Fellow of The Canadian Academy of Engineering, winner of the EY Entrepreneur Of The Year™ 2017 Pacific Awards Technology category, past Chair of LifeSciences British Columbia, and serves on multiple medical device company boards, bringing over 30 years of experience in medical device innovation and commercialization.

David Jen is the Managing Director of Finance and Corporate Development at X, Alphabet's Moonshot Factory, where he leads diligence and capital allocation across moonshot projects including Waymo, Verily, Wing, and Intrinsic. A Tufts University graduate with a BA in International Relations and Economics, he brings two decades of finance and strategy experience from roles at J.P. Morgan, Thomson Reuters, Yahoo, and Google before joining X in 2015, and also serves as a Venture Partner at UP.Partners, board member at Quincus, and board member of the Tufts University Derby School of Entrepreneurship.

Dr. Jeffrey Ojemann is Vice-Chair for Discovery and Professor in the Department of Neurological Surgery at the University of Washington, Senior Vice President and Chief Medical Officer at Seattle Children's Hospital, and holder of the George A. Ojemann Endowed Chair for Epilepsy Research. He serves as President of the American Society of Pediatric Neurosurgery (2023) and co-chairs the prestigious NINDS K12 program, specializing in epilepsy surgery, pediatric neurosurgery, and pioneering research in brain-computer interfaces and cortical function.

Dr. Daniel Donoho is a pediatric neurosurgeon at Children's National Hospital and Assistant Professor at George Washington University, where he leads NIH-funded research creating artificial intelligence systems that improve surgical safety and training. He is the founder of the Surgical Data Science Collective (SDSC), pioneering the use of computer vision and machine learning to revolutionize video-based surgical education, and has developed breakthrough AI applications for surgical performance assessment and global knowledge-sharing in neurosurgery.

Dr. Andre Machado is Chief of the Neurological Institute at Cleveland Clinic and the Charles and Christine Carroll Family Endowed Chair in Functional Neurosurgery, where he leads one of the world's premier neuroscience programs and serves as Associate Chief of Staff. His pioneering research in deep brain stimulation has earned him the NIH Director's New Innovator Award, and he co-leads the Cleveland Clinic Brain Study, the first long-term investigation aimed at identifying biomarkers for preventing and curing neurodegenerative disorders.

Dr. Anthony "Tony" Asher is President of the Advocate Health Neuroscience Institute (formerly Atrium Health Neuroscience Institute), Vice Dean for Neurosciences at Wake Forest University, and former President of both the Congress of Neurological Surgeons and the American Association of Neurological Surgeons. He co-founded the National Neurosurgery Quality and Outcomes Database and the American Spine Registry, leading revolutionary quality data programs that have enrolled over 450,000 patients and fundamentally transformed neurosurgical practice standards across North America.

Dr. Russell Lonser is a distinguished neurosurgeon and Chair of the Department of Neurological Surgery at The Ohio State University, recognized as one of the world's preeminent authorities on the nervous system and widely regarded as the "godfather" of convection-enhanced delivery (CED) therapies. His pioneering research has revolutionized direct drug delivery to the brain, developing breakthrough convective delivery strategies that bypass the blood-brain barrier to treat brain tumors, and his work has established the foundational principles and clinical applications of CED that are now used globally in neurosurgical practice.

Dr. Leeza Maron is a neuropsychologist with specialized expertise in brain function assessment and cognitive rehabilitation, and Associate Professor of Psychiatry and Neurology at Oregon Health & Science University where she serves as Director of the Division of Psychology. She was instrumental in creating and developing OHSU's Clinical Psychology PhD Program, serving as the Former Director of Clinical Training for the program that was established in 2019, and currently leads medical science initiatives at DeepWell DTx focusing on the intersection of neuroscience and psychology in developing therapeutic approaches for neurological and mental health conditions.

Dr. Norman Rosenthal is a pioneering psychiatrist and researcher best known for his groundbreaking work in seasonal affective disorder (SAD) and light therapy, having first described and named SAD in the 1980s while working at the National Institute of Mental Health. He has authored numerous publications on depression, light therapy, and circadian rhythms, including bestselling books such as "Winter Blues" and "Transcendence," and has been instrumental in developing therapeutic approaches for mood disorders that have helped millions of patients worldwide through evidence-based treatments for depression and seasonal mood variations.

Dr. Devapratim Sarma is a bioengineering expert who earned his Ph.D. in Bioengineering with a focus on Neural Engineering from the University of Washington in 2017, where he worked extensively in Dr. Jeffrey Ojemann's GRIDlab developing electrocorticographic brain-computer interfaces for cognitive and motor rehabilitation. His pioneering research includes co-authoring breakthrough studies on direct brain-to-brain interfaces in humans and optimizing BCI systems for continuous control applications, with significant contributions to companies like Synchron in advancing brain-computer interface technologies for medical applications.

Kyle Smith is the CEO of Reell Precision Manufacturing, holding a Ph.D. in Solid State Chemistry from Brown University and a BS in Chemistry from the University of Missouri at Columbia. He is a recipient of the prestigious 2022 Dayton Award from the Caux Round Table for Moral Capitalism, recognizing his exceptional leadership in ethical business practices, and has led Reell through remarkable growth including over 700% share price increase while maintaining the company's commitment to employee welfare, community service, and sustainable business practices.

Mike Springer served as Vice President of Technology & Operations at the Jacobs Institute in Buffalo, where he led the growth of the innovation center and its Idea to Reality (i2R) program, supporting early-stage inventors, startups, and strategic OEMs in developing next-generation vascular and neurological devices. He brings extensive expertise in medical device operations, manufacturing industrialization, and business development across endovascular devices, minimally invasive surgery, surgical navigation, robotics, and artificial intelligence, and currently leads manufacturing efforts at Starfish Medical while maintaining a broad network throughout the medical device ecosystem.

Bob Tunheim is a Partner and Co-Practice Leader of the Private Equity Group at Ballard Spahr LLP, a prestigious Am Law 100 firm, where he represents clients in mergers and acquisitions, corporate finance transactions, and general business matters. With over three decades of experience in private equity since establishing his first fund in 1991, he provides counsel to numerous private equity groups nationwide in their formation, investments, and liquidation transactions, and has been consistently recognized in The Best Lawyers in America and selected as a Super Lawyer for his expertise in M&A and corporate law.

Craige Thompson is the founder and principal patent attorney of Thompson Patent Law, holding a B.S. in Electrical & Computer Engineering from the University of Wisconsin and a J.D. (cum laude) from University of Wisconsin Law School, along with Professional Engineer (PE) licensure. He is the author of the bestselling book "Patent Offense," which reveals battle-tested approaches for maximizing the financial value of patent portfolios, and has successfully served an impressive client roster including Apple, Google, Intel, Microsoft, Boston Scientific, and numerous Fortune 100 companies in protecting complex technologies ranging from electrical engineering to medical devices.

Larry Harris is the Founder and Owner of Athorus, PLLC, a registered patent attorney with global experience in counseling high technology companies in developing, obtaining, and licensing patents, and formerly served as Associate General Counsel of Intellectual Property for Amazon. He has substantial experience in portfolio development, conflict resolution, and providing in-house intellectual property support for both U.S. and international clients, and is a member of the Washington State Bar, District of Columbia Bar, and California State Bar, with admission to practice before the United States Patent and Trademark Office and multiple federal courts.

Beth LaBreche is an accomplished global Fortune 500 executive and entrepreneur who founded the award-winning LaBreche PR agency in 1990, which was later acquired by Gage marketing agency, and subsequently served as Vice President of Enterprise Marketing and Communications at CHS Inc., a Fortune 100 energy, grains and foods company. She is nationally recognized for her leadership in marketing and strategic positioning and communications for change and risk management, and currently operates LaBreche PR Consulting, guiding B2B public and private companies through transformation during pivotal times, with particular focus on manufacturing and medical devices industries.

Jerry Mattys served as Chief Executive Officer of Tactile Medical (now Tactile Systems Technology Inc.) from January 2005, leading the company through significant growth and successfully taking it public on NASDAQ in July 2016 as the only Minnesota IPO that year. Under his leadership, Tactile Medical became a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency, with revenue increasing 32% in 2015 to $62.9 million and the company reaching a peak market capitalization of over $1.2 billion by 2019.

Jeff Harris is a Quality and Regulatory professional who was instrumental in creating the first truly integrated quality management system iQMS and served as lead author on DeepWell's groundbreaking 510(k) FDA submission for biofeedback software development kit technology that enables video games and interactive media to be cleared as digital therapeutics. His regulatory work helped establish the framework for therapeutic gaming applications and gave rise to the immersive medicine community, while his early contributions to the NeuFluent organization brought expertise in quality systems and regulatory strategy to advance neuroscience innovation.

Emily Hatlelid is a Scientific Technician, researcher, and regulatory professional whose work has contributed to vast literature reviews and compiling of data, helping identify key mechanisms of action for brain computer interface and immersive medicine applications. As a founding contributor to both DeepWell and NeuFluent, she has been instrumental in establishing the scientific foundation and regulatory framework that supports the development of therapeutic gaming technologies and neuroscience innovation platforms.

Jalen Douglas is an early investigator on the use of media for the treatment of mental health who conducted the first literature reviews and co-authored the original patents identifying key elements of game design that were integral to immersive medical device design. He is developing expertise in the social impacts of media and AI, holds patents for immersive medicine, and is the creator of Elevate, a digital therapeutic and integrated tool set designed to help improve executive function, contributing foundational research that helped establish the scientific basis for therapeutic gaming applications.

Matthew Douglas is a founding researcher for DeepWell DTx who contributed to early research around the impacts and intersections between gaming and social media for therapeutic applications. His work contributed to the foundational patents for DeepWell and helped inform the game mechanics that were built into the initial products and systems, establishing key design principles that bridge entertainment and therapeutic efficacy in digital health interventions.